Sign in
Taking people in United StatesPhase 2

PeRampanel fOr Status ePilEpticus pRophylaxis Post-cardiac Arrest

Key facts

Who runs it
University of California, San Francisco
Where
San Francisco, United StatesSee the site
Trial code
Status
Recruiting
Phase
Phase 2
People taking part
52 people, planned
Started
20 May 2024
Expected to end
20 Oct 2027
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Perampanel
  • Placebo
Record updated
29 July 2026

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 11 criteriaShow less

Who can take part

  • Age ≥18 years old
  • Non-traumatic, out-of-hospital cardiac arrest
  • Comatose on admission - defined as not following commands
  • Return of spontaneous circulation (ROSC) within less than 45 minutes from the time of cardiac arrest (defined as the time of 911 or EMS (emergency medical services) witnessed arrest)
  • Admission to the intensive care unit at Zuckerberg San Francisco General Hospital

Who cannot take part

  • Acute cerebral hemorrhage or infarction
  • Severe liver impairment with liver function tests five times above the upper limit of normal
  • Electrographic or electroclinical seizures diagnosis using American Clinical Neurophysiology criteria confirmed by an epileptologist after cardiac arrest
  • Severe kidney function impairment with creatinine clearance inferior to 30 ml/min
  • Pregnancy
  • Prisoner

This trial is currently available in United States.

  • Zuckerberg San Francisco General HospitalSan Francisco, United StatesContact: Edilberto Amorim, MDTaking people

About the trial

What the trial wants to find out

Brain injury is the main cause of death and disability for patients surviving cardiac arrest resuscitation and seizures are diagnosed in up to a third of these patients. The investigators are proposing a pilot randomized placebo-controlled clinical trial to evaluate the safety and feasibility of perampanel use for post-cardiac arrest status epilepticus (PCARSE) prevention after cardiac arrest.

The 2 groups in the trial

  • PerampanelExisting treatment, for comparison

    Perampanel oral load of 24mg upon randomization followed by 8mg oral dose daily for four more days (second dose one day after load and total treatment duration is 5 days)

  • PlaceboPlacebo, for comparison

    Placebo oral load upon randomization followed by daily placebo oral dose administration for four more days (second dose one day after load and total placebo administration duration is 5 days)

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Record updated
29 July 2026